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The aim of the following case report is to provide a description of acute lymphoblastic
leukemia (ALL) in a patient with Netherton syndrome (NS). A 15-year-old male with
NS was referred with suspicion of acute leukemia. Severe anemia, leukocytosis,
thrombocytopenia, and elevated CRP level were demonstrated in pre-hospital laboratory
tests. Physical examination revealed generalized ichthyosiform erythroderma. ALL was
diagnosed on the basis of bone marrow biopsy. The patient was initially classified
as CNS3 status. No signals indicating fusion of BCR/ABL1, ETV6, and RUNX1
genes and MLL gene rearrangement were found in the cytogenetic analysis. The
patient was qualified for chemotherapy and treated according to ALL IC-BFM 2009
protocol for high-risk ALL. During induction therapy, severe skin toxicity occurred (WHO
grade III), which prompted the modification of treatment down to intermediate-risk
strategy. In the course of reinduction therapy, severe chemotherapy-induced adverse
drug reactions occurred, including progression of skin toxicity to WHO grade IV. The
patient achieved complete remission. In view of life-threatening toxicities and the
confirmed complete remission, intensive chemotherapy regimen was discontinued and
maintenance treatment was started. Because of the baseline CNS3 status, the patient
received cranial radiotherapy. Whole exome sequencing (WES) was used to identify
disease-associated mutations. WES revealed two germline mutations: a novel premature
termination variant in SPINK5 (p.Cys510∗), along with a novel potentially pathogenic
variant in NUP214 (p.Arg815Gln). Somatic mutations were known pathogenic variants of
JAK2 (p.Arg683Gly), IL17RC (p.Ala303Thr), and potentially pathogenic non-synonymous
variants of TTN (p.Gly1091Arg and p.Pro17245Leu), ACTN2 (p.Ile143Leu), TRPV3
(p.Arg729∗), and COL7A1 (p.Glu2842fs) genes. Currently, the patient continues
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maintenance chemotherapy, with stable status of skin lesions and no features of ALL
relapse. To our knowledge, this is the first report of ALL in a patient with NS. As has
been presented, in such patients, optimal treatment according to the current protocols
is extremely difficult. WES was used to confirm the diagnosis of Ph-like ALL in our patient.
The detection of JAK2 gene mutation offers the possibility of therapy personalization. A
specific signature of rare germline variants and somatic mutations can be proposed as
a factor predisposing to the co-incidence of ALL and NS.
Keywords: Netherton syndrome, malignancy, leukemia, children, mutation
BACKGROUND
Netherton syndrome (NS) (OMIM #256500) is a rare autosomal
recessive disorder. It is caused by mutations of Kazal type 5
(SPINK5) gene, encoding a serine protease inhibitor LEKTI (1, 2).
Its incidence is estimated at 1:200,000 births (3) and ∼200 cases
described in the literature. It is one of ichtyosis syndromes, a
clinically and genetically heterogeneous group of disorders of
cornification (4). Typical examples include the triad of congenital
ichthyosiform erythroderma, trichorrexis invaginata (a hair shaft
abnormality), and lesions resembling atopic dermatitis, but
phenotypic features are variable in individual patients. The
impairment of the epidermal barrier leads to thermoregulatory
dysfunction, fluid and electrolyte disturbances, as well as
frequent recurrent skin and respiratory infections. Other features
may include intellectual disability, neurological deficits, and
growth retardation.
The issue of carcinogenesis in NS is still a matter of
debate. According to current knowledge, NS does not belong to
syndromes with proven genome instability (5). However, in most
cases, a higher incidence of skin and mucous membrane tumors
was described, particularly in early adolescence (6–9). Several
hypotheses were proposed to explain this phenomenon. In one
patient, human papillomavirus (HPV) DNA was preferentially
detected inmalignant lesions, and it was speculated that impaired
epidermal defense mechanisms could have promoted latent HPV
DNA persistence in the skin (10). Recurrent infections typical for
NS may suggest that immunodeficiency, including abnormalities
of memory B cells and natural killer cells, which are common
in NS, might be associated with cutaneous carcinogenesis (11).
Moreover, long-term ultraviolet (UV) and immunosuppressive
therapies used in the treatment of patients with NS may promote
the development of cancer in adulthood (7). Importantly, no
direct relationship between LEKTI deficiency and skin cancers
has been proven so far.
The association of NS and hematological malignancies is
a different and very rare issue. To date, only a few cases of
coexistence of acute leukemia, the most common childhood
malignancy, with various types of inherited ichthyoses have been
described (12). According to our knowledge, no case report of
acute leukemia in patients with NS has been published to date
and possible mechanisms of such a coincidence are not known.
The suspected causes included an effect of immunodeficiency,
an increased chromosome fragility and breakage rate, or a
simple matter of chance (12). However, in previous case reports,
high-throughput genome sequencing methods have not been
used to exclude the genetic background of the coexistence of
these disorders.
CASE PRESENTATION
We report a 15-year-old male diagnosed with NS in infancy
and referred to the Department of Pediatric Oncology and
Hematology with suspected acute leukemia. His medical history
was remarkable for high-grade fever (up to 40◦C) lasting 1
week. A day before admission, syncope occurred immediately
after rising from bed. Based on alarming symptoms and patient’s
congenital disease, a complete blood count and C-reactive
protein (CRP) were performed by a primary care physician.
Severe anemia (hemoglobin level 3.8 g/dl), leukocytosis (white
blood cell count 14,000/µl), thrombocytopenia (platelet count
16,000/µl), and elevated CRP level (63 mg/dl) were found.
Physical examination revealed hyposthenic body habitus, growth
retardation, and generalized ichthyosiform erythroderma.
Bone marrow biopsy was performed as a part of routine
surveillance, and it revealed 98% of lymphoblasts. Common
type acute lymphoblastic leukemia (ALL) was diagnosed and
was qualified as L1 subtype according to FAB classification.
Immunophenotype examination of bone marrow cells revealed
the presence of population of abnormal lymphoblasts (about
98%) presenting SSClow and low expression of CD45 (CD45-
dim). A normal male karyotype (46,XY) was found in the
bone marrow cytogenetic analysis. Split-signal-FISH of bone
marrow cells showed no BCR/ABL1 fusion genes. No MLL gene
rearrangements as well as ETV6 and RUNX1 fusion genes were
found. No additional validation of FISH negative results was
performed. Due to the high level of suspicion of central nervous
system involvement and intraretinal hemorrhages, the patient
was classified as CNS3 status at baseline. Cerebrospinal fluid
examination revealed no lymphoblasts. In addition, a high IgE
level of 10,700 IU/ml was found.
The treatment according to ALL IC-BFM 2009 protocol was
introduced. A satisfactory response to glucocorticoid prophase
was seen. Bone marrow aspiration on day 15 revealed 1.5%
blasts and minimal residual disease (MRD) of 11%. Complete
remission with MRD of 0.087% was achieved on day 33.
According to the treatment protocol, the assessment of MRD
on day 15 is crucial for qualification of a patient to a specific
risk group. Based on this result, the patient was stratified
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FIGURE 1 | Generalized ichthyosis linearis circumflexa on the patient’s trunk.
FIGURE 2 | Large erythematous plaques and intensive scaling on the patient’s
limbs.
as high-risk group and an appropriate chemotherapy regimen
was started. During the induction phase, severe skin toxicities
appeared (WHO grade III), which prompted the modification
of treatment down to intermediate-risk strategy. The patient
received induction, early intensification, consolidation (3 of 4
methotrexate cycles), and an initial phase of reinduction (until
day 19). In the course of chemotherapy, severe adverse drug
reactions occurred: skin toxicity (WHO grade IV: Figures 1,
2), glucocorticoid-induced diabetes, hepatotoxicity, syndrome
of inappropriate antidiuretic hormone hypersecretion (SIADH),
as well as recurrent infections. After initial reinduction, the
complete remission was confirmed with negative MRD result.
Due to the life-threatening toxicities and in view of achieving a
complete remission, intensive chemotherapy was discontinued
and maintenance treatment was introduced. Considering the
initial CNS3 status and the risk of central nervous system
infection caused by repeated lumbar punctures, therapeutic
cranial radiotherapy in the dose of 18Gy in 12 fractions was used.
Moreover, the negative MRD status was additionally confirmed.
Currently, 2 years from the start of ALL treatment,
the patient’s general health status is good. Maintenance
chemotherapy is continued with stable skin lesions and no signs
or symptoms of ALL relapse.
Infectious Complications
At initial evaluation, positive IgG antibodies against Toxoplasma
gondii and Epstein-Barr virus (EBV) viral capsid antigen (VCA)
were detected.
In view of immunodeficiency associated with NS, the
patient received prophylactic phenoxymethylpenicillin, co-
trimoxazole, and antifungal agents throughout the treatment
period. Nevertheless, conjunctivitis and sinusitis occurred during
the treatment, with Pseudomonas aeruginosa etiology confirmed
in both cases, and nasopharyngeal colonization with this
pathogen was also found.
The patient was febrile several times. At the beginning
of consolidation, he was admitted with high-grade fever
approaching 39.5◦C due to progression of dermatitis. An
extended course of low-dose oral prednisone as a treatment for
dermatitis was continued until the third cycle of methotrexate.
Topical treatment included emollients, hydrocortisone-tanin,
and hydrocortisone-cholesterol-based ointments. Repeated
problems with central venous access occurred due to NS-
related dermatitis. A Hickman central venous catheter was
implanted into the right internal jugular vein but healing
was incomplete and removal of the catheter was necessary.
After the third methotrexate cycle, the patient presented
with signs and symptoms of sepsis with fever up to 40◦C.
Staphylococcus haemolyticus was cultured in blood samples
taken from the catheter. The catheter was removed and another
one was implanted, followed by subsequent implantation
of several peripherally inserted central catheters (PICC).
These also required removal as P. aeruginosa, S. haemolyticus,
Staphylococcus epidermidis, and Enterococcus faecium were
subsequently detected in blood cultures. Swab cultures revealed
saprophytic bacterial flora with Staphylococcus simulans, S.
epidermidis, and Enterococcus faecalis. Because of sepsis with
fever up to 39◦C, fungal pneumonia, and diarrhea, the patient
received only an initial phase of reinduction chemotherapy.
Description of Laboratory Investigations
and Genetic Tests
Genetic tests were performed to explore the possible genetic
basis of NS and ALL coexistence. Genomic DNA was extracted
from bone marrow cells collected at ALL diagnosis according
to the standard protocols. WES was performed on Illumina
HiSeq X Ten platform, using sequencing libraries generated with
Agilent SureSelect All Exon V6 Kit and TruSeq DNA Library
Preparation Kit. The obtained 16.6 giga-bases of aligned sequence
data resulted in >200× mean coverage of the target capture
regions. The raw reads from FASTQ files were aligned to hs38DH
reference genome using BWA (version 0.7.15). Resulting BAM
files were post-processed with Sentieon software implementing
the equivalent GATK 3.5 Best Practices protocol, and the GVCFs
files were generated. The personalized panel of genes was
created based on Human Phenotype Ontology (HPO) (version:
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April 13, 2017). The panel consists of genes associated with
the phenotype: “HP:0006721 Acute lymphoblastic leukemia;”
“HP:0008064 Ichthyosis,” and “ORPHA:634, OMIM:256500
Netherton syndrome” (385 genes total). SNVs (single nucleotide
variants) and INDELs (short insertions and deletions) were
discovered via joint genotyping of GVCFs.
The resulting VCF was annotated and filtered using an
analysis of designed workflow. After discarding variants with
QUAL < 30, remaining variants were annotated on variant
and gene level. The variant level annotations consisted of flags
designating the presence of variant OMIM, PubMed, or HGMD
databases), names of diseases associated with a given variant
and their clinical significance [ClinVar (version: April 4th, 2017)
and MITOMAP (version: January 19th, 2017) databases], and
their frequencies in 1000 Genomes, ExAC, gnomAD,MITOMAP,
and local database. Variants were also annotated with impact
prediction scores: SnpEff annotations (version: 4.3i), SIFT—
deleteriousness score (version: February 2th, 2017), and GERP
and PhastCons—evolutionary conservation scores. Variant-level
filtering removed variants more frequent than 1% in 1000
Genomes, ExAC, or MITOMAP populations and variants with
SnpEff impact LOW or MODIFIER. Gene-level filtering retained
variants located in genes present in the panel.
Among the genes associated in HPO database with autosomal
dominant model of NS, ALL, and ichthyosis inheritance,
there were 10 significant variants identified. Most of those
mutations have high SIFT deleteriousness score (<0.11) and
high evolutionary conservation (GERP > 4.7 and PhastCons =
1). A novel premature termination germline variant in SPINK5
(p.Cys510∗) was identified. Three variants have been detected
in ALL-related genes: a known pathogenic somatic variant in
JAK2 gene (p.Arg683Gly) coding a non-receptor tyrosine kinase,
a known pathogenic somatic variant of IL17RC (p.Ala303Thr),
and a previously non-described germline variant in NUP214
(p.Arg815Gln). In addition, two different missense variants in
TTN gene associated with titin isoform N2-B (p.Gly1091Arg
and p.Pro17245Leu) as well as a novel potentially significant
variant in ACTN2 (p.Ile143Leu) were identified. There were
also two interesting variants in TRPV3 gene (p.Arg729∗) in
a highly conserved region (GERP > 4.0 and PhastCons =
1) as well as in COL7A1 (p.Glu2842fs) with lower level of
conservation. WES also detected a remaining variant in RPL15
gene (p.Arg189Gln) associated with Diamond-Blackfan anemia.
Results of the analysis are presented in abbreviated form
in Table 1.
DISCUSSION OF THE UNDERLYING
PATHOPHYSIOLOGY AND SIGNIFICANCE
OF THE CASE
Our case report is related to the diagnosis and treatment of
ALL in a patient with NS, which, to our knowledge, has not
been reported to date. As presented above, several modifications
of the treatment regimen due to exacerbations of skin lesions
were necessary. Moreover, numerous infectious complications
were seen, which also impeded the oncological treatment. WES
analysis revealed the presence of several significant genetic
mutations that may explain the etiology of ALL in patients
with NS.
Despite the initial stratification of the patient to the high-
risk group, it was necessary to apply an intermediate-risk ALL
treatment protocol and subsequently to prematurely terminate
the intensive phase of the treatment. As has been demonstrated,
rigorous adherence to the treatment regimens designed for
appropriate risk groups is associated with excellent outcomes
(13). Conversely, non-compliance with chemotherapy protocols
causes an increased risk of relapse (14–16). Long-term follow-up
will be necessary in our patient due to this undertreatment and
unknown outcomes of ALL in NS.
Severe skin toxicity was one of the most important
factors limiting optimal ALL treatment in the presented case.
We hypothesized that the intensive chemotherapy protocol
predisposed our patient to extensive skin lesions development.
Currently, NS treatment is exclusively symptomatic and is
based on the use of emollients, keratolytic agents, antibiotics,
and histamine H1 receptor antagonists (17). Corticosteroids of
moderate strength as well as calcineurin inhibitors should be
used on limited body areas, because of the high risk of systemic
absorption (18, 19). Recent reports concerning the successful
use of intravenous immunoglobulins (11) and infliximab (20)
appear to represent new therapeutic options. The extensive use of
these agents along with the emerging new treatment options will
probably reduce chemotherapy-induced skin toxicity in NS who
need oncological treatment and allow the use of more aggressive
treatment strategies.
Recurrent infectious complications were another problem
that occurred during the ALL treatment. A number of different
locations were affected and various alarming pathogens were
involved. The issue of recurrent infections in NS has been
repeatedly reported in the literature. Their frequency has
been estimated at ∼30% (21). In recent years, Renner et al.
(11) have shown reduced memory B cells and decreased
NK cell cytotoxicity. Moreover, treatment with intravenous
immunoglobulins resulted in clinical improvement and
temporarily increased NK cell cytotoxicity. Hannula-Jouppi
et al. (22) in a study conducted in 11 Finnish patients with NS
confirmed the previous observations on NK cell immaturity
and dysfunction as well as reduced levels of memory B
cells. Additionally, elevated serum IgG4 levels were detected,
which has not been reported previously. Interestingly, both
studies presented data concerning impaired post-vaccination
immune response in NS (11, 22). The above results have led
to the inclusion of NS in the current classification of primary
immunodeficiencies (23).
According to the literature, up to 10% of cancer cases
that occur in children are associated with well-characterized
predisposing genetic syndromes (24). However, the low incidence
of genetic factors in the etiology of childhood leukemia and
absence of NS in leukemia-related syndromes suggest the
pure coincidence of both diseases (25). The results of WES
should be interpreted with extreme caution. We have recently
demonstrated its effectiveness in the assessment of a pediatric
patient with coincidence of two cancers (26). The detected variant
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TABLE 1 | Selected somatic and germline genetic variants detected in the patient.
Gene symbol Position of sequence change Reference SNP ID number Variant type Classification according to ACMG
SPINK5 p.Cys510* – Germline Pathogenic
JAK2 p.Arg683Gly rs1057519721 Somatic Likely pathogenic
NUP214 p.Arg815Gln rs749833713 Germline Uncertain significance
IL17RC p.Ala303Thr rs145516404 Somatic Pathogenic
TTN p.Gly1091Arg rs72647870 Somatic Benign
TTN p.Pro17245Leu rs754702040 Somatic Likely benign
ACTN2 p.Ile143Leu – Somatic Uncertain significance
TRPV3 p.Arg729* rs11654533 Somatic Uncertain significance
COL7A1 p.Glu2842fs rs566181351 Somatic Uncertain significance
RPL15 p.Arg189Gln rs764132899 Somatic Uncertain significance
in the SPINK5 gene is a genetic confirmation of the inherited
NS. Several other mutations have also been considered as cancer-
related. Therefore, we decided to discuss their potential impact
on our patient’s disease.
A novel variant in SPINK5 gene as a germline mutation was
detected in our patient. The discovered p.Cys510∗ mutation
is associated with occurrence of premature termination
codon. Based on a recent large systematic review, about 80
different mutations in 144 families have been described so far.
Interestingly, genotypes with mutations located more upstream
in LEKTI correlate with more severe phenotypes, which may
explain the wide variety of clinical phenotypes of NS (1). Most
of the mutations described so far have also been associated
with premature termination (4). The use of genome sequencing
technology provides a unique opportunity to identify novel
potentially pathogenic variants.
TRPV3 is another skin-specific gene whose mutation
was detected in our patient. Activation of TRPV3 in skin
keratinocytes causes skin barrier formation, hair growth, wound
healing, temperature sensing, itch, and pain perception (27).
Its dysfunction leads to the occurrence of Olmsted syndrome
(28), allergic dermatitis (29), and also promotes the formation
of scars (30). Potentially, the coexistence of SPINK5 and TRPV3
mutations could lead to a more aggressive course of NS, but so
far, this relationship has not been described in the literature.
WES analysis also detected several leukemia-related genes.
It should be emphasized that the number of comprehensively
characterized whole genomes of ALL patients is relatively
small. Janus kinase 2 (JAK2) is a member of the non-receptor
tyrosine kinase family. JAK2 activating mutations occur in 8.6%
BCR/ABL1-negative, high-risk pediatric ALL cases (31). Majority
of the detected somatic mutations, including our patient,
involved the 683rd amino acid residue, which is an important
amino acid for the JH2 domain-mediated negative auto-
regulation of JAK2 activity (32). The second somatic mutation
associated with the JAK pathway regulation was a variant of
interleukin-17 receptor (IL17RC) gene (33). Nucleoporin 214
(NUP214) is required for cell cycle and nucleocytoplasmic
transport. Its abnormalities are found rarely in pediatric
leukemias, mostly in T-ALL patients. Five fusion genes associated
with NUP214 have been described so far (34). Their occurrence
is associated with worse prognosis due to the chemotherapy
resistance (35). In our patient, the germline mutation in NUP214
(p.Arg815Gln) was found. Based on the Clinvar database,
ribosomal protein L15 mutation (RPL15) is found in Diamond-
Blackfan anemia. This syndrome is associated with hematological
malignancies such as myelodysplastic syndrome and acute
myeloid leukemia (36). In our patient, however, phenotypic
manifestations of the detected mutation were not found (37).
Considering the negative BCR/ABL1 fusion result in the
cytogenetic test and the presence of pathogenic JAK2, IL17RC,
NUP214, and RPL15 mutations in the WES, the diagnosed
leukemia can be initially qualified as the recently identified
Philadelphia chromosome-like acute lymphoblastic leukemia
(Ph-like ALL). Sequencing studies have shown that Ph-like
ALL represents a complex genomic landscape with diverse
genetic alterations. Unfortunately, we did not perform the
analysis of prognostically significant IKZF1 alterations in the
current case report (38). Ph-like ALL prevalence is ∼12% in
children and 21% in adolescents (39). Most patients with Ph-
like ALL have positive MRD after remission induction (40).
In a large analysis of 1,725 childhood, adolescent, and young
adult ALL cases, Ph-like ALL was associated with event-free
and overall survival rates equal or inferior to high-risk ALL
subtypes (41). The improvement of the unfavorable prognosis
can be achieved by the introduction of targeted therapy.
Preclinical studies with patient-derived xenograft cells show the
high efficacy of JAK2 inhibitors. Ruxolitinib and momelotinib
suppress cells with JAK2 mutations. Moreover, momelotinib
also inhibits cells without these mutations, which may suggest
some additional mechanisms of action (42). It may also be
effective in patients with IL17RC mutations. Preliminary clinical
observations indicate high effectiveness of these agents. Roberts
et al. (41), using genetic methods, identified a small subgroup
of high-risk patients with Ph-like ALL in whom targeted
therapy was subsequently used. Of the 12 patients who began
therapy (including 3 patients treated with ruxolitinib), rapid and
sustained responses were found in 11 patients for whom follow-
up data were available. According to expert opinions, JAK2
inhibitors may be considered as an add-on, but not as substitutes
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for chemotherapy in patients with JAK2mutations (42). Possibly,
an inclusion of a JAK2 inhibitor in a standard maintenance
chemotherapy regimen might also improve the prognosis in
our patient. However, prospective, randomized, multicenter
trials are necessary for approval of the novel targeted drugs in
pediatric population.
CONCLUDING REMARKS
To our knowledge, we present the first case report of ALL in a
patient with NS. As has been shown, optimal treatment according
to current protocols is extremely challenging in such patients.
WES allowed for detection of two novel germline mutations
and initial qualification of leukemia diagnosed in our patient as
Ph-like ALL. Moreover, detection of JAK2 gene mutation may
offer an opportunity to personalize the treatment. A specific
signature of rare germline variants and somatic mutations can
be proposed as a predisposing factor to the coexistence of ALL
and NS.
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